On June 12, 2025, Context Therapeutics Inc. held its Annual Meeting where shareholders approved a reverse stock split and ratified CohnReznick LLP as the independent auditor for 2025, with 74.37% of shares represented. The reverse stock split ratio will be between 1-for-5 and 1-for-50, as decided by the Board.